<DOC>
	<DOC>NCT00092924</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.</brief_summary>
	<brief_title>Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Primary Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or recurrent NSCLC Previously treated and failed to respond to standard therapy or progressed after standard therapy 18 years of age or older Primary Received a nonFDA approved investigational agent within the last 4 weeks. Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies Infection requiring antibiotics or hospitalization within the last 2 weeks HIV, HepatitisB, HepatitisC Pregnant or breastfeeding women Major surgery within the last 4 weeks History of other cancers within the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>